Kairos Pharma, Ltd.

AMEX: KAPA · Healthcare · Biotechnology

PublicHQ Los Angeles, CA · Los AngelesCIK 0001962011Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 52DQ —GM —SS 20

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$5.4M

Employees

as of 2026-08-23

Market cap

$6.2M

as of 2026-08-23

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$5.4M-$5.4M2025

Operating income-$5.6M-$5.6M2025

Total assets$6.5M$6.5M2025

Liabilities$992.0k$992.0k2024

Equity$6.3M$6.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Kairos Pharma, Ltd.’s financial profile?

Kairos Pharma, Ltd. earned -$5.4M in FY2025 net income.

Peers · Healthcare

Imagion Biosystems Limited——Acurx Pharmaceuticals, Inc.——Cardiac Biotech Solutions Inc.——Eastgate Biotech Corp.——CYduct Diagnostics, Inc.——Reviva Pharmaceuticals Holdings, Inc.——

Neighbors

Los Angeles →

The Walt Disney Company$94.4B72B Public Storage$4.8B80B+Southern California Gas Company PFD SER A 6%——Ares Management Corporation$5.6B68B Live Nation Entertainment, Inc.$25.2B76B+Rocket Lab USA, Inc.$601.8M50D

Key facts

CEOJohn S. Yu

SectorHealthcare

IndustryBiotechnology

HeadquartersLos Angeles, CA

ExchangeAMEX: KAPA

Employees4

IPO date2024-09-16

Latest filings

8-K2026-08-21 10-Q2026-08-12 8-K2026-07-22 8-K2026-07-15 8-K2026-06-30 8-K2026-06-04 DEF 14A2026-05-22 8-K2026-05-18

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.